Hospital de la Santa Creu i Sant Pau
If you are the contact person for this centre and you wish to make any changes, please contact us.
Neurologist in charge of the “Central Autoimmune Neurology Unit” at the Hospital de la Santa Creu i Sant Pau in Barcelona
Specialist doctor at the Clinical Epidemiology and Public Health Service of the Hospital de Sant Pau in Barcelona and Patient Safety Expert
Director of the Internal Medicine Department and head of the Fibromyalgia and Chronic Fatigue Syndrome Functional Unit at the Hospital Sant Pau in Barcelona
Clinical Head of the Thoracic Surgery Department at the Hospital de la Santa Creu i Sant Pau in Barcelona, co-coordinator of the CASSANDRA lung cancer screening project and director of Integrated Research Projects in Thoracic Oncology at the Spanish Society of Pneumology and Thoracic Surgery (SEPAR)
Director of the Memory Unit of the Neurology Service of the Hospital de la Santa Creu i Sant Pau and director of the Alzheimer's Unit at the Fundació Catalana Sindrome de Down
Director of the Dermatology Department of the Hospital de la Santa Creu i Sant Pau and professor at the Autonomous University of Barcelona
Neurologist in the Neuromuscular Diseases Unit - Autoimmune Neurology - Neuromuscular Lab
Hospital de la Santa Creu i Sant Pau & Institut de Recerca Biomèdica Sant Pau, Barcelona
Specialist in Immunology at the Hospital de Sant Pau in Barcelona and secretary of the Spanish Society of Immunology
Clinical Head of the Headache and Neuralgia Unit at the Neurology Department of the Hospital de la Santa Creu i Sant Pau in Barcelona
Neurologist at the Memory Unit of the Hospital de la Santa Creu i Sant Pau.
A few weeks ago, a press release from the Biogen and Eisai companies reported significant results from their lecanemab antibody for the treatment of early-stage Alzheimer's. The data from the phase 3 trial are now published in the New England Journal of Medicine, coinciding with the CTAD conference on Alzheimer's disease clinical trials in San Francisco. Data from the phase 3 clinical trial are now published in the New England Journal of Medicine, coinciding with the 15th CTAD Alzheimer's disease clinical trials conference in San Francisco.
A double clinical trial has analyzed the efficacy of ruxolitinib cream in treating depigmentation associated with vitiligo. The results are published in the New England Journal of Medicine.
Science magazine has published a report revealing multiple indications of fraud in one of the most cited publications on Alzheimer's disease. We explain what it means for the science that studies this disease.